Consolidation chemotherapy for adults with AML in first remission: Is there a best choice?

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2067-2069

  Stone, Richard M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DIAZIQUONE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; INTERLEUKIN 2; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DRUG MEGADOSE; EDITORIAL; EVENT FREE SURVIVAL; HEALTH CARE QUALITY; HUMAN; INDUCTION CHEMOTHERAPY; INTENTION TO TREAT ANALYSIS; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE;

EID: 84890476235     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.6886     Document Type: Editorial

References (22)

1. Burnett A, Wetzler M, Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487-494, 2011
2. Cassileth PA, Begg CB, Bennett JM, et al: A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 63:843-847, 1984
3. Marcucci G, Haferlach T, Döhner H: Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 29:475-486, 2011
4. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896-903, 1994
5. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
6. Neubauer A, Maharry K, Mrózek K, et al: Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study. J Clin Oncol 26:4603-4609, 2008
7. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008
8. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
9. Kolitz JE, George SL, Marcucci G, et al: P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116:1413-1421, 2010
10. Moore JO, George SL, Dodge RK, et al: Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 105:3420-3427, 2005
11. Weick JK, Kopecky KJ, Appelbaum FR, et al: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 88:2841-2851, 1996
12. Löwenberg B, Pabst T, Vellenga E, et al: Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027-1036, 2011
13. Bishop JF, Matthews JP, Young GA, et al: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710-1717, 1996
14. Schiach M, ET a: High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: Results of the prospective randomized AML-2003 trial. J Clin Oncol 31:2094-2102, 2013
15. Plunkett W, Liliemark JO, Estey E, et al: Saturation of ara-CTP accumulation during high dose ara-C therapy: Pharmacologic rationale for intermediatedose ara-C. Semin Oncol 14:159-166, 1987
16. Petersdorf S, Kopecky K, Stuart RK, et al: Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Ann Meet Abstr 114:790, 2009
17. Schaich M, Röllig C, Soucek S, et al: Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: Results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 29:2696-2702, 2011
18. Brune M, Castaigne S, Catalano J, et al: Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: Results of a randomized phase 3 trial. Blood 108:88-96, 2006
19. Buyse M, Squifflet P, Lange BJ, et al: Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 117:7007-7013, 2011
20. Kindler T, Lipka DB, Fischer T: FLT3 as a therapeutic target in AML: Still challenging after all these years. Blood 116:5089-5102, 2010
21. Vo TT, Ryan J, Carrasco R, et al: Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151:344-355, 2012
22. Zeng Z, Shi YX, Samudio IJ, et al: Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113:6215-6224, 2009